<DOC>
	<DOCNO>NCT00932438</DOCNO>
	<brief_summary>This multicentre , open label , control phase study design assess effectiveness chemoembolization LC Beads , without systemic chemotherapy , treatment unresectable liver metastases patient colorectal cancer .</brief_summary>
	<brief_title>Drug-Eluting Bead , Irinotecan ( DEBIRI ) Therapy Liver Metastasis From Colon Cancer With Systemic FOLFOX6</brief_title>
	<detailed_description>This multicentre , open label , prospective , randomize , control phase I/II study design assess clinical performance chemoembolization LC Bead , load irinotecan combination intravenous chemotherapy bevacizumab versus intravenous chemotherapy combination bevacizumab treatment unresectable liver metastases patient colorectal cancer .</detailed_description>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Neoplasms , Second Primary</mesh_term>
	<mesh_term>Colonic Neoplasms</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Leucovorin</mesh_term>
	<criteria>Inclusion : Patients 18 year age , race sex , histologic radiologic proof colorectal cancer liver , able give inform consent , eligible . Patients least one measurable liver metastasis , size &gt; 1cm ( modify RECIST criterion ) Patients liver dominant disease define ≥80 % tumor body burden confine liver Patients patent main portal vein ECOG Performance Status score &lt; 2 Life expectancy &gt; 3 month Nonpregnant acceptable contraception premenopausal woman . Hematologic function : ANC ≥ 1.5 x 109/L , platelet ≥75 x109/L , INR ≤1.3* ( *If patient anticoagulant , must able stop medication temporarily prior TACE must INR ≤1.3 prior receive TACE ) Adequate liver function measure : Total bilirubin ≤ 2.0mg/dl , ALT , AST ≤5 time ULN , albumin ≥2.5g/dl , Adequate Hemoglobin Hematocrit measure ( Male : approximate 45 62 % ; approximate Female : 37 48 % ) Hemoglobin ( Male : approximate 13 18 gm/dL Female : approximate 12 16 gm/dL ) . If patient asymptomatic Hemoglobin male 10 12.9 Female 9.5 11.9 wish transfuse still eligible treatment . Adequate renal function ( creatinine ≤ 2.0mg/dl ) Women child bear potential fertile men require use effective contraception ( negative serum βHCG woman childbearing age ) Signed , write informed consent Patient least one month treatment Stage III colorectal cancer Patient least one year treatment Stage IV colorectal cancer . patient candidate curative treatment , recover chemotherapeutic toxicity ' may experience . '' Less 60 % liver tumor replacement Exclusion : `` Any patient eligible curative treatment ( i.e . resection radiofrequency ablation ) . Note : resectability define single tumor &lt; 5cm adequate liver function define : Total bilirubin ≤ 2.0mg/dl '' nonresectability include patient great 6 , tumor close blood vessel , patient hepaticpulmonary shunting , patient poor performance '' Active bacterial , viral fungal infection within 72 hour study entry Women pregnant breast feeding Allergy contrast medium manage standard care ( e.g . steroid ) , make magnetic resonance imaging ( MRI ) compute tomography ( CT ) contraindicate . Presence another malignancy exception cervical carcinoma situ stage I basal squamous carcinoma skin . Any contraindication hepatic embolization procedure : Large shunt determine investigator ( pretesting TcMMA require ) Severe atheromatosis Hepatofugal blood flow Main portal vein occlusion ( e.g . thrombus tumor ) Other significant medical surgical condition , medication treatment , would place patient undue risk would preclude safe use chemoembolization would interfere study participation Patients prior contraindication use irinotecan therapythis would include chronic inflammatory bowel disease bowel obstruction , history severe hypersensitivity reaction irinotecan hypochloride , trihydrate , lactic acid excipients Camptostar , severe bone marrow failure , history Gilbert Syndrome concomitant use St. John 's Wort Patients prior contraindication use fluorouracil , oxaliplatin , leucovorin bevacizumab</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2011</verification_date>
	<keyword>colon cancer</keyword>
	<keyword>liver metastasis</keyword>
</DOC>